Background: It is unclear how the extent of surgical lymph node clearance influences prognosis after surgery for esophageal cancer.
Esophageal cancer is the eighth most common cancer globally (1) . The overall five-year survival is only 10%, and among curatively treated patients the five-year survival is 30% (2) . Surgery is a cornerstone of curatively intended treatment, although addition of neo-adjuvant therapy has improved the long-term survival (3, 4) . Esophageal cancer typically spreads multidirectionally via the lymphatic system, hence lymph nodal status is a strong prognostic factor (5) . This implies that radical lymphadenectomy might be an important measure to improve survival (6) . An extensive lymphadenectomy mainly aims to ensure oncological completeness of the resection and counteract tumor recurrence (5, 7) . However, extensive lymphadenectomy increases the surgical trauma, which might increase postoperative morbidity and mortality (7, 8) . Although based article on limited scientific evidence, clinical guidelines recommend extensive (two-field) lymphadenectomy (9) (10) (11) (12) . Yet because the role of lymphadenectomy remains controversial (5, 6, 8, (13) (14) (15) in practice, its extent varies greatly between surgeons. We aimed to assess the extent of lymphadenectomy during esophageal cancer surgery in relation to survival in an unselected cohort with long and complete follow-up.
Methods

Study Design
The design of this study has been described in detail elsewhere (16, 17) . In brief, a comprehensive nationwide cohort included 98% of all curatively treated esophageal cancer patients in Sweden between 1987 and 2010. The follow-up ended at death, emigration, or end of the study period (December 2012), whichever occurred first. Clinical data were collected through a nationwide Swedish network of clinicians established in the mid 1990s (18) . The Regional Ethical Review Board in Stockholm, Sweden approved the study.
Study Cohort
All patients in Sweden with a diagnosis code representing esophageal cancer (150.0, 150.8, or 150.9) according to the 7th version of the International Classification of Diseases (ICD7) were identified from the Swedish Cancer Registry, which has 98% nationwide coverage regarding esophageal cancer cases (19, 20) . Patients who underwent surgery were identified from the Swedish Patient Registry, which has an excellent (99.6%) positive predictive value for esophageal surgery (21) . Information on patients' comorbidity and hospital admittances were also collected from the Swedish Patient Registry (21) . The Swedish Causes of Death Registry provided accurate death dates and causes of death. The linkages between registries and the identification of medical records were enabled by virtue of the Swedish personal identity number, assigned to each Swedish resident upon birth or immigration. Relevant medical records containing operation notes and histopathological reports of the cohort members were retrieved from all Swedish hospitals where esophageal cancer surgery was conducted.
Surgery
Open transthoracic esophageal resection with intrathoracic anastomosis was the dominating procedure (95%). The preferred esophageal substitute was a pulled-up gastric tube, anastomosed to the proximal esophagus in the thorax or neck. There was no consensus about the extent of lymphadenectomy.
Histopathology
The histopathological assessments of the surgical specimens were carefully reviewed. One reviewer, who was kept blinded for the study outcomes, filled in a predefined protocol. The accuracy of the histopathological review was assessed by two researchers who independently reviewed 100 records, demonstrating high accuracy (>90% concordance) (16) . Data regarding lymphadenectomy, neo-adjuvant therapy, and tumor stage (including T-stage), location, and histology were obtained from these records. The use of neoadjuvant therapy has been introduced only more recently in Sweden, and when used neoadjuvant therapy was typically a combination of chemotherapy and radiotherapy. Tumor stage was classified according to the 6 th version of the TNM classification of the Union Internationale Contre le Cancer (UICC), because some information necessary to stage according to the 7 th edition of the TNM classification was unavailable when the cohort was initiated (22) . Nonradical resections were defined as microscopic (R1 resection) or macroscopic (R2 resection) tumor involvement of the proximal or distal margins of the resected specimen (23) . Because R1 and R2 resection is not considered curative surgery (12) , patients with such resection and those with distant metastasis were excluded.
Lymph Node Variables
The number of lymph nodes resected was the main study exposure. Secondary exposures were number of metastatic lymph nodes and ratio of metastatic to total number of lymph nodes.
Mortality
The primary study outcome was all-cause overall five-year mortality. The four secondary outcomes were: disease-specific overall five-year mortality, short-term overall mortality (defined as any death within 90 days of surgery), longer-term overall mortality (counted from 90 days to five years of surgery), and diseasespecific longer-term mortality. The definitions of short-term and longer-term mortality were based on research showing that patients who die within the first 90 days of surgery usually die from postoperative complications, while most patients who survive 90 days and die within five years have tumor recurrence as the cause of death. Deaths occurring later than five years after surgery are usually not a result of tumor recurrence.
Statistical Analysis
Potential survival differences between exposure groups were analyzed using a multivariable Cox-proportional hazards ratio model, providing hazard ratios (HRs) with 95% confidence intervals (CIs) with adjustment for potential confounding factors. The lymph node variables were analyzed both as continuous variables and divided into medians and quartiles. Because the number of removed nodes was low in the two first quartiles (range 0-6), they were collapsed into one, which was used as reference category. We tested for a linear trend using contrasts, and because there was no statistically significant trend in categories for number of lymph nodes removed, we decided to use these variables as categorical variables in the models. All hazard ratios were adjusted for seven predefined potential confounding factors: 1) age (categorized into three groups: <65, 65-75, or >75 years), 2) sex (male or female), 3) (1987-1992, 1993-1998, 1999-2004, or 2005-2010) . In subgroup analysis, hazard ratios were calculated for early (Tis-T1) and later T-stages (T2 and T3) in relation to lymph node exposure. This subgroup analysis was decided a priori because early article T-stage tumors less often have lymph node metastasis, while more advanced T-stage tumors often are associated with lymph node metastasis, and the gain in extensive node removal was expected to be higher in more advanced tumors.
Tests of interaction were performed between the exposure variables and calendar period, T-stage, and tumor histology. Potential interactions between lymph node clearance and T-stage, neo-adjuvant treatment and calendar periods were also tested. If there was a statistically significant interaction between lymph node removal and any of these covariates, it was taken into account in the multivariable analyses. Esophageal sublocation was also evaluated as a confounder, but because it did not add additional information to the model (P > .77 in all models) it was not included in the final models. Missing values on any of the covariates were handled using two well established strategies (24): 1) Missing data were included in a separate category in the multivariable model or 2) patients with missing data were excluded from the multivariable analysis. Since the hazard ratios did not differ between these strategies, only the results from strategy 1 are presented. Moreover, because the hazard ratios were similar in the adjusted and unadjusted analyses, only the adjusted hazard ratios are presented.
Alpha at 5% and two-sided tests were used for statistical significance, while for trend tests one-sided tests were used. SAS 9.2 (SAS Institute, Inc., Cary, NC) was used to perform all statistical analyses.
Results
Patient Characteristics
Among 1304 identified patients, 260 patients with nonradical resection (R1 or R2 resections or distant metastasis) were excluded, leaving 1044 patients for final analysis. Characteristics of the included patients are presented in Table 1 . Most patients were younger than 75 years (84.9%) and male (74.8%). The median number of removed lymph nodes was seven (range 0-114). The number of removed lymph nodes was similar between T stages; the mean was 11.0 in the early tumor group (T0-T1), 10.9 in the T2 group, and 11.8 (95% CI = 10.7 to 12.9) in the T3 group. The number of removed lymph nodes increased with calendar periods; from 4.9 in 1987-1992, 6.0 in 1993-1999, and 10.8 in 1999-2004, to 18.9 in 2005-2010. The mean number of removed nodes was lower among patients with squamous cell carcinoma who had neoadjuvant therapy (5.9) compared with those without neoadjuvant therapy (11.6), while no such difference was found for adenocarcinoma (13.0 nodes both with and without neoadjuvant therapy).
Comparing patients in the first two and last two quartiles of lymphadenectomy (median), the distribution did not differ much regarding age, sex, T stage, or neo-adjuvant treatment, while there were differences in comorbidity, tumor histology, annual surgeon volume, and calendar periods ( Table 1) .
The 30 day postoperative mortality decreased during the study period from 7.8% in 1987-1992 to 1.7% in 2005-2010. The 90-day postoperative mortality was 8.4% (n = 88). The overall absolute five-year mortality was 81.2% (n = 848). Among those who died, 76.1% (n = 795) had a recorded tumor recurrence, ie, disease-specific mortality.
Overall Five-Year Mortality
There was no influence of a higher number of lymph nodes removed analyzed as a continuous variable on overall five-year mortality (HR = 1.00, 95% CI = 0.99 to 1.01). Similarly, a higher number of lymph nodes removed did not decrease the overall mortality in the categorized analyses (Table 2) . Patients in the third (7-15 nodes) and fourth (16-114 nodes) quartiles of removed nodes had no decreased overall five-year mortality compared with those in the lowest two quartiles (<7 nodes) (HR = 1.13, 95% CI = 0.95 to 1.35 and HR = 1.17, 95% CI = 0.94 to 1.46, respectively). Rather, the results indicated an increased hazard ratio of mortality when comparing the quartiles 1+2 with quartiles 3+4 (HR = 1.21, 95% CI = 1.03 to 1.42). In the early T-stages (Tis-T1) the corresponding HR was 1.53 (95% CI = 1.13 to 2.06), while the number of lymph nodes resected among patients in more advanced T-stages (T2-3) did not influence mortality, when comparing the medians (HR = 1.02, 95% CI = 0.82 to 1.27) ( Table 2) . We also analyzed each T stage separately, but no statistically significantly decreased mortality was found with higher number of removed nodes in any individual T stage (data not shown).
An increasing number of metastatic lymph nodes had a strong negative influence on the overall five-year mortality ( Table 2 ). The hazard ratio in the fourth quartile of metastatic lymph nodes (>3 metastatic nodes) was 2.75 (95% CI = 2.27 to 3.33), compared with the lowest two quartiles (no metastatic nodes). The increased point hazard ratio of overall five-year mortality associated with node metastasis was slightly higher in the earlier compared with the more advanced T stages (Table 2) . Similarly, a higher metastatic to nonmetastatic lymph node ratio resulted in a strongly increased overall five-year risk of mortality, particularly in earlier T stages (Table 2) .
In analyses restricted to a later calendar period (2000-2010), the results were similar to the entire study period, except for smaller differences in point hazard ratios between T stages (Table 3 ).
Short-term Mortality
A higher number of lymph nodes removed, an increasing number of metastatic lymph nodes, or a higher lymph node ratio did not statistically significantly influence 90-day mortality (Supplementary Table 1 , available online). The were no associations between number of lymph nodes removed and 90-day mortality in analyses starified by T stage (data not shown).
Longer-term Overall Mortality
The 90-day to five-year overall mortality was similar to the overall five-year mortality, and showed no decreased mortality with a higher number of resected nodes (Supplementary Table 1 , available online). The influence of metastatic lymph nodes and lymph node ratio was similar to the overall mortality results (Supplementary Tables 1 and 3 , available online).
Disease-Specific Five-Year Mortality
The disease-specific five-year hazard ratios (Table 4) were similar to the overall hazard ratios ( Table 2) . Compared with the lowest two quartiles, the hazard ratios for disease-specific mortality were 1.16 (95% CI = 0.94 to 1.42) and 1.20 (95% CI = 0.91 to 1.58) in the third and fourth quartile of removed nodes, respectively (Table 4) . Also, the disease-specific hazard ratios were similar to the overall hazard ratios regarding T stage-specific results (Table 4) . Results regarding number of metastatic lymph nodes and lymph node ratio on the five-year disease-specific mortality were similar to the overall mortality results (Table 4;  Supplementary Table 2 , available online).
article
Disease-Specific Longer-term Mortality
The disease-specific longer-term mortality hazard ratios (Supplementary Table 2 , available online) were similar to the overall hazard ratios (Supplementary Table 1 , available online), as well as the T stage-specific hazard ratios (Supplementary  Table 3 , available online). The analysis restricted to a later calendar period of surgery (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) showed similar results to that of the entire study period, including T stage-specific results (Supplementary Table 4 , available online).
Interactions
There were no statistically significant interactions between the exposure variables and calendar period, T stage, or tumor histology, except for a statistically significant interaction between calendar period and number of metastatic lymph nodes only.
Discussion
This study found no support for the hypothesis that a higher number of resected lymph nodes during esophageal cancer surgery improves long-term survival, independent of T stage.
Because it is unfeasible to study effects of number of removed nodes in a randomized trial, the observational study design remains. The fluctuations in lymphadenectomy between surgeons provided good opportunities for comparisons in this observational study. Follow-up was complete by virtue of complete Swedish registries. Adjustments for all established article prognostic factors counteracted confounding. Changes in surgical techniques and in neo-adjuvant treatment over time and centralization of surgery were taken into account by adjusting for calendar periods, use of neo-adjuvant therapy, and surgeon annual volume of esophagectomy. A potential weakness is that the pathological examination of the specimens varied between pathologists. However, although this could lead to misclassification of the lymphadenectomy and thus dilute effects, any such error would be unlikely to explain why a higher number of examined nodes did not improve survival at all. Moreover, the strong associations between identified metastatic nodes and survival indicate validity of the node assessment. We used pathologic T stage because it is considered more accurate than clinical T stage, but pathologic T stage could be affected by neoadjuvant therapy. However, the adjustment for neoadjuvant therapy should act against bias in the present study. Finally, the large sample size provided sufficient power for the main analyses, although the T stage-specific results had a lower precision. The lack of decreased mortality with more extensive lymphadenectomy in this study challenges clinical guidelines recommending two-field lymphadenectomy (9) (10) (11) (12) . The scientific evidence supporting a more extensive lymphadenectomy (twofield or even three-field lymphadenectomy) is limited. However, in a study using data from a consortium of institutions, a greater lymphadenectomy was associated with better survival in most tumor stages (25) . This finding might be explained by stage migration issues (11) or confounding, eg, by annual surgeon volume because more experienced surgeons tend to remove more nodes (17) . Our results are in line with two well-designed studies that found no survival difference between a more extensive lymphadenectomy via transthoracic esophagectomy and a more limited lymphadenectomy by a transhiatal approach-a large Dutch randomized clinical trial (26, 27) and a large British cohort study (28) . Moreover, a randomized trial comparing twofield with three-field lymphadenectomy found no difference in survival (29) . Attempts to identify a minimum lymphadenectomy to optimize survival and tumor staging have led to controversy (30) , with recommendations ranging widely from six to 23 nodes (5, 6, 8, 26, (31) (32) (33) (34) (35) . The present study indicates that extensive lymphadenecomy might even increase mortality in early tumor stages.
Presence of metastatic lymph nodes and a high lymph node ratio strongly predicted survival in this study, which confirms the results of previous studies (30, 36, 37) . The N stage of the UICC TNM 7 classification (updated in 2010) seems to predict mortality more accurately than the 6 th version (38, 39) , which is supported by the present study, where a higher number of involved nodes better predicted survival than presence or absence of metastatic nodes only.
A tailored lymphadenectomy that enables selective removal of metastatic nodes while leaving nonmetastatic nodes in place might be ideal, but it is currently difficult to identify metastatic nodes (40) . Improvements in preoperative nodal staging and new biomarkers that can visualize metastatic nodes could tailor future nodal removal. Sentinel node techniques are complicated by the multidirectional spread and high occurrence of skip metastasis (40) .
It might be relevant to compare the lack of survival benefit with extensive lymphadenectomy of this study with developments in other tumors. In breast cancer surgery, for example, extensive lymphadenectomy did not improve survival, but increased morbidity, why a less extensive and more tailored approach to lymphadenectomy has been adopted. An interpretation is that lymphadenectomy during esophageal cancer article surgery might not improve survival simply because positive nodes indicate disseminated disease, while nonmetastatic nodes do not need to be removed.
In conclusion, this large and population-based cohort study with adjustment for prognostic factors suggests that a more extensive lymphadenectomy does not improve survival after surgery for esophageal cancer. These results challenge current guidelines and need confirmation in further research.
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